Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK, Safety and Tolerability of LXI-15028 in Healthy Chinese Subjects
NCT03458650Phase 1Completed
- Sponsor
- Shandong Luoxin Pharmaceutical
- Start
- Mar 2018
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of tegoprazan in gastroesophageal reflux disease (GERD) and duodenal ulcer (3 arms), sponsored by Shandong Luoxin Pharmaceutical. Primary endpoints: Maximum Plasma Concentration, Time to Maximum Plasma Concentration and 4 more. Started Mar 2018; status: completed.
02
Drugs
tegoprazan
03
Conditions
gastroesophageal reflux disease (GERD)duodenal ulcer
Beyond the preview
Go deeper on NCT03458650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03458650.